MaxCyte Files 8-K on Exit Costs and Disclosures

TL;DR

MaxCyte 8-K filed 9/22/25 - reporting on exit costs and financial disclosures.

AI Summary

MaxCyte, Inc. filed an 8-K on September 22, 2025, reporting on cost associated with exit or disposal activities, Regulation FD disclosure, and financial statements and exhibits. The filing does not contain specific dollar amounts or detailed descriptions of the exit or disposal activities.

Why It Matters

This filing indicates MaxCyte is undergoing restructuring or divesting assets, which could impact future financial performance and strategic direction.

Risk Assessment

Risk Level: medium — The filing mentions 'Cost Associated with Exit or Disposal Activities,' suggesting potential restructuring or divestitures which carry inherent business risks.

Key Players & Entities

• MAXCYTE, INC. (company) — Registrant
• September 22, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-40674 (identifier) — SEC File Number
• 52-2210438 (identifier) — IRS Employer Identification No.
• 9713 Key West Avenue, Suite 400 (address) — Principal executive offices
• Rockville, Maryland 20850 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.01 — ge on which registered Common Stock, $0.01 par value MXCT The Nasdaq Stock Mar
• $2.9 million — ill incur an aggregate of approximately $2.9 million of pre-tax, cash charges. The Company e
• $1.8 million — expected to consist of the following: $1.8 million in severance and termination-related be
• $0.6 million — severance and healthcare continuation; $0.6 million in costs associated with employees enga
• $0.4 million — rmany, France, and the United Kingdom; $0.4 million in wages and benefits required under th
• $0.1 million — or affected employees in Maryland; and $0.1 million in other associated costs, including le
• $13.6 m — nnualized cost savings of approximately $13.6 million, which will begin to be realized

Filing Documents

• mxct-20250922x8k.htm (8-K) — 46KB
• mxct-20250922xex99d1.htm (EX-99.1) — 10KB
• mxct-20250922xex99d1001.jpg (GRAPHIC) — 6KB
• 0001104659-25-092162.txt ( ) — 184KB
• mxct-20250922.xsd (EX-101.SCH) — 3KB
• mxct-20250922_lab.xml (EX-101.LAB) — 16KB
• mxct-20250922_pre.xml (EX-101.PRE) — 10KB
• mxct-20250922x8k_htm.xml (XML) — 5KB

05. Costs Associated with Exit or Disposal Activities

Item 2.05. Costs Associated with Exit or Disposal Activities. On September 22, 2025, the Board of Directors of MaxCyte, Inc. approved a workforce reduction plan (the "Plan") as part of the Company's ongoing efforts to streamline operations, improve its cost structure, and align resources with strategic priorities. The Plan is expected to result in a reduction of approximately 34% of the Company's workforce globally, which includes both directly employed personnel and individuals engaged through third-party employer-of-record ("EOR") arrangements. In connection with the implementation of the Plan, the Company currently estimates that it will incur an aggregate of approximately $2.9 million of pre-tax, cash charges. The Company expects to incur these charges primarily during the third quarter of 2025 and payment of these charges are expected to occur through Q2 2026. These charges are expected to consist of the following: $1.8 million in severance and termination-related benefits for directly employed personnel, including cash severance and healthcare continuation; $0.6 million in costs associated with employees engaged through EOR arrangements, including severance, benefits, and statutory notice-period wages administered in accordance with applicable labor laws in jurisdictions such as Germany, France, and the United Kingdom; $0.4 million in wages and benefits required under the Maryland Economic Stabilization Act (commonly referred to as the "Mini-WARN Act"), which mandates 60 days' advance notice or pay in lieu thereof for affected employees in Maryland; and $0.1 million in other associated costs, including legal fees, consulting services, and administrative expenses related to implementing the Plan. The actual timing and amount of these charges may differ from the Company's current estimates due to a variety of factors, including the finalization of severance terms, jurisdiction-specific legal requirements, third-party administration of EOR-related obliga

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On September 22, 2025, the Company issued a press release announcing the Plan. A copy of the press release is attached hereto as Exhibit 99.1. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release, dated September 22, 2025 104 Cover Page Interactive Data (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MaxCyte, Inc. Dated: September 22, 2025 By: /s/ Douglas Swirsky Douglas Swirsky Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR